Development of freeze-dry kits containing imatinib and different chelating agents: characterization, stability and cytotoxicity studies

Development of freeze-dry kits containing imatinib and different chelating agents: characterization, stability and cytotoxicity studies

The current study aims to develop new freeze-dry kits containing Imatinib and different chelating agents for breast cancer treatment and diagnosis as theranostics. Four formulations (Kit-1, Kit-2, Kit-3, and Kit-4) were prepared, and the characterization of formulations was assessed utilizing particle size, polydispersity index, zeta potential, fourier transform infra-red analysis, ultraviolet spectrum analysis, differential calorimetry, and thermogravimetric analysis. They were also evaluated for stability at different storage conditions and cytotoxicity effect on fibroblast NIH-3T3 cells. The particle size, polydispersity index, and zeta potential of developed formulations were found to be between 6953.6 ±131.6 and 5888.3 ± 131.6 nm, 0.481 ± 0.24 and 0.319 ± 0.18, -594.5±59.6 and -477.3 ± 25.32 mV, respectively. Fourier transform infra-red analysis, ultraviolet spectrum, differential calorimetry, and thermogravimetric analysis have proven that IMT and chelating agents formed complexes in kit formulations. Also, they exhibited stable facility and above 90% of cell viability on fibroblast NIH-3T3 cells. By the result of our study, kit formulations can be a favorable drug delivery system in the treatment and diagnosis of breast cancer with a non-toxic effect on healthy cells.

___

  • [1] Cohen Martin H, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, Khin Maung U, Staten AM, Pazdur R. Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia. Clin Cancer Res. 2002; 8(5): 935–942.
  • [2] Waller CF. Imatinib Mesylate. Recent Results in Cancer Res. 2018; 212: 1-27. [CrossRef]
  • [3] Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond). 2008; 3(2): 137-140. [CrossRef]
  • [4] Haque MA, Vasudha BD, Surekha B, Gouthami C, Hari Priya R, Yakamma B. Development of uv-spectrophotometric method for the determination of imatinib mesylate in bulk and formulation. Int J Pharm Res Health Sci. 2016; 4(2): 1130–1135.
  • [5] Danaei MM, Dehghankhold SA, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, M. R. Mozafari SMR. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018; 10(2): 57. [CrossRef]
  • [6] Bhojya Naik H, Siddaramaiah S, Ramappa PG. Thermogravimetric analysis of Cobalt(II)-Dothiepin complexes. J Therm Anal Calorim. 1999; 55(3): 841–49. [CrossRef]
  • [7] Guimarães KL, Inês Ré M. Lipid nanoparticles as carriers for cosmetic ingredients: The first (SLN) and the second generation (NLC). In: Beck R, Guterres S, Pohlmann A. (Eds). Nanocosmetics and Nanomedicines New Approaches For Skin Care. Springer, Verlag Berlin Heidelberg, 2011 pp. 101–122.
  • [8] Imatinib, DrugBank Online. https://go.drugbank.com/drugs/DB00619 (accessed on 1 March 2021).
  • [9] Gundogdu E,Karasulu HY, Koksal C, Karasulu E. The novel oral imatinib microemulsions: Physical properties, cytotoxicity activities and improved Caco-2 cell permeability. J Microencapsul Micro and Nano Carriers. 2013; 30(2): 132-142.
  • [10] Othman MF, Elise V, Costa I, Tanapirakgul M, Cooper MS, Imberti C, Lewington VJ, Blower PJ, Terry SYA. In vitro cytotoxicity of auger electron-emitting [67Ga]Ga-Trastuzumab. Nucl Med Biol. 2020; 80(81): 57–64. [CrossRef]
  • [11] Mohini G, Sharma R, Amirdhanayagam J, Sarma HD, Rangarajan V, Dash A, Das T. Formulation and clinical translation of [177Lu] Lu-Trastuzumab for radioimmunotheranostics of metastatic breast cancer. RSC Med Chem. 2021;12: 263-277. [CrossRef]
  • [12] International Atomic Energy Agency. Development of kits for 99mTc radiopharmaceuticals for infection imaging, IAEA-TECDOC-1414, IAEA, Vienna. 2004.
  • [13] Smita JP, Rajendra CD, Priya PD. Development of uv-spectrophotometric method for the determination of imatinib mesylate (ITM) in Bulk and Formulation. Asian J Pharm Clin Res. 2013; 6(3): 54–57.
  • [14] Bożena K, Górniak A, Marciniak DM, Mucha I. Molecular mobility and stability studies of amorphous imatinib mesylate. Pharmaceutics. 2019; 11(7): 304. [CrossRef]
  • [15] Maude R, Wiest J, Saedtler M, Harlacher C, Gutmann M, Zottnick SH, Piechon P, Dix I, Buschbaum KM, Holzgrabe U, Meinel L, Galli B. Bioinspired co-crystals of imatinib providing enhanced kinetic solubility. Eur J Pharm Biopharm. 2018; 128: 290–299. [CrossRef]
Journal of research in pharmacy (online)-Cover
  • Yayın Aralığı: 6
  • Yayıncı: Marmara Üniversitesi
Sayıdaki Diğer Makaleler

Synthesis, characterization and antimicrobial evaluation of new 2-(2-thienylcarbonyl)hydrazono-3-alkyl/aryl-4-thiazolidinone and 2-aryl-3-(2-thienylcarbonyl)amino-4-thiazolidinone derivatives

Dilek ŞATANA, Efe Doğukan DİNCEL, Süheyla ÖZBEY, Nuray ULUSOY-GÜZELDEMİRCİ

Liquid Chromatographic Determination of pKa Value of 1- (2-methylbenzonitrile)-3-benzylbenzimidazolium bromide as a Drug Candidate in Acetonitrile-Water Binary Mixtures

Ebru ÇUBUK DEMİRALAY, Zehra ÜSTÜN, İlkay KONÇE, Senem AKKOÇ

Metal nanoparticles for miRNA detection

Ayca KARASAKAL

An In-Silico Approach for Analysing the interplay of Hepatitis B viral X protein with Human Adaptin protein.

Prachie SHARMA, Kapila KUMAR, Kamal RAWAL

Development and Assessment of Mitoxantrone and 4- Methyl Umbelliferone Nanoemulsions for Chemotherapeutic Potential on MCF-7 Cell Line

Vineeta MEENA, Azka GULL, Neha JAIN, Swati MADAN, Dhruv KUMAR, Rajani MATHUR, Satyendra KUMAR RAJPUT

Acute hyperglycemia causes oxidative stress which is prevented by vitamin E pretreatment in healthy rabbits

Gökçen TELLİ, İnci KAZKAYASI, Serdar UMA, Aylin BALCI

Novel pyrazole substituted oxazole derivatives: Design, insilico studies, synthesis & biological activities

Srilakshmi SINGAGARI, Raja SUNDARARAJAN

Formulation of a natural nanosystem based on β- cyclodextrin/arginine/xanthan to increase antifungal activity of Salvia officinalis essential oil from Algeria (Bejaïa, Kalaa n'Ath Abas)

Yacine NAIT BACHIR, Naima SAHRAOUI, Zahia CHEURFA, Meriem MEDJKANE, Amel HADJ ZIANE

The effects of N(1)-2,4-dihydroxybenzylidene-N-(4) hydroxybenzylidene-S-methyl-thiosemicarbazidatooxovanadium( IV) on testicular damage in streptozotocininduced diabetic rats

Bahri ÜLKÜSEVEN, Refiye YANARDAĞ, Sevim TUNALI, Tülay BAL-DEMİRCİ

The Role of Metformin and Aerobic Exercise on The Hepatic Ischemia-Reperfusion Injury in Streptozotocin- Induced Diabetic Mice

Gökçen TELLİ, Orçin TELLİ-ATALAY